Alnylam Pharmaceuticals
ALNY
£218.49
Share price
11.75%
Change (1 day)
88.69%
Change (1 year)
Categories
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.
Alnylam Pharmaceuticals (ALNY) - Total assets
Total assets on the balance sheet as of December 2024 : £3.26 Billion
According to Alnylam Pharmaceuticals 's latest financial reports the company's total assets are £3.26 Billion. A company’s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.
Alnylam Pharmaceuticals - Total assets on balance sheet (from 2003 to 2024)
Total assets by year
| Year | Total assets | Change |
|---|---|---|
| 2024-12-31 | £3.37 B | 12.39% |
| 2023-12-31 | £3.00 B | 2.55% |
| 2022-12-31 | £2.93 B | 8.61% |
| 2021-12-31 | £2.69 B | 7.98% |
| 2020-12-31 | £2.49 B | 36.85% |
| 2019-12-31 | £1.82 B | 47.23% |
| 2018-12-31 | £1.24 B | -15.94% |
| 2017-12-31 | £1.47 B | 44.21% |
| 2016-12-31 | £1.02 B | 9.39% |
| 2015-12-31 | £0.93 B | 34.93% |
| 2014-12-31 | £0.69 B | 171.99% |
| 2013-12-31 | £0.25 B | 43.32% |
| 2012-12-31 | £0.17 B | -1.92% |
| 2011-12-31 | £0.18 B | -28.8% |
| 2010-12-31 | £0.25 B | -14.36% |
| 2009-12-31 | £0.29 B | -21.4% |
| 2008-12-31 | £0.37 B | 52.26% |
| 2007-12-31 | £0.24 B | 102.86% |
| 2006-12-31 | £0.12 B | 114.85% |
| 2005-12-31 | £57.03 M | 65.62% |
| 2004-12-31 | £34.43 M | 75.08% |
| 2003-12-31 | £19.66 M | 95.74% |
| 2002-12-31 | £10.04 M |
Total Assets for similar companies or competitors
| Company | Total assets | differencediff. | Country |
|---|---|---|---|
 | £0.78 B | -76.09% | 🇺🇸 USA |
 | £29.11 B | 790.56% | 🇺🇸 USA |
 | £3.05 B | -6.53% | 🇺🇸 USA |
 | £1.69 B | -48.11% | 🇺🇸 USA |
 | £72.3 M | -97.79% | 🇺🇸 USA |
 | £78.84 B | 2,311.47% | 🇨🇭 Switzerland |
 | £106.56 B | 3,159.26% | 🇫🇷 France |
 | £30.32 B | 827.50% | 🇮🇱 Israel |